https://www.selleckchem.com/pr....oducts/Vorinostat-sa
Only four patients had stopped looking for the next HCD. Patients often respond to late choice HCDs. There are responders and failures at each time point and they are difficult to predict. There is no justification for restricting the number of HCDs that can be tried for RA. Key Points • Less than 2% of our RA patients required 4 or more higher cost drugs. • Fourth to sixth choice drugs still worked in 50 to 55% of patients. • There is no justification for CCGs restricting the number of drugs that can be tried. Patients often re
Like
Comment
Share
